Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal
RPTH Journal/LinkedIn
Sep 3, 2026, 00:44

Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal

RPTH Journal shared a post on LinkedIn about a recent article by Jacob Lund et al, adding:

“Same goal. Different molecular strategy. Which FVIIIa mimetic gets there how?

This new RPTH study directly compares denecimig (Mim8), zemocimig (NXT007), and emicizumab under the same experimental conditions.

The next-generation mimetics take strikingly different routes:

  • Zemocimig – highest FIXa–FX complex assembly affinity
  • Denecimig – lower affinity, but dramatically higher catalytic activity
  • Yet denecimig and zemocimig produced remarkably similar thrombin-generation profiles, with both showing greater potency than emicizumab.

Different engineering strategies – similar enhancement of hemostatic potential.

An intriguing mechanistic look at the evolving generation of FVIIIa-mimetic therapies for hemophilia A.”

Title: Mechanism of action and impact on thrombin generation of denecimig (Mim8), emicizumab, and zemocimig (NXT007): comparative analysis using sequence-identical analogs

Authors: Jacob Lund, Thomas Egebjerg, Jais Rose Bjelke, Mirella Ezban

RPTH Journal

More posts featuring RPTH Journal on Hemostasis Today.

FVIIIa-mimetic therapies Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Jacob Lund Jais Rose Bjelke Medicine Mirella Ezban RPTH Journal Thomas Egebjerg
NewsFeed